Chinese pharmaceutical stocks have been sluggish since November, even as policymakers have released a dense stream of positive news—a striking divergence. The A-share SW Pharmaceutical & Biotech Index and Hong Kong’s Hang Seng Healthcare Index have pulled back in tandem, with declines concentrated in innovative drugs and the CXO complex, the most crowded trades of the year. Chen Chen, head of China healthcare research at UBS Securities, said at a recent media briefing that the sector has shown an earnings inflection point, and identified biotech, CRO and AI drug discovery as the three key areas to watch, arguing that China’s pharmaceutical industry is shifting from reliance on the domestic market toward a new paradigm of “innovation plus globalization.”
According to China Merchants Securities, the SW Pharmaceutical & Biotech Index fell 2.87% from November 9 to 13, underperforming the CSI 300 Index by 1.93 percentage points and ranking 26th among the 31 SW first-tier industry sectors. In Hong Kong, the Hang Seng Healthcare Index fell 1.61% over the same period but still outperformed the Hang Seng Index by 1.84 percentage points. The Hong Kong healthcare correction extended into this week; as of the November 17 close, the Hang Seng Healthcare Index stood at 3,470.87 points, down further from 3,559.03 on November 13.
Within the sector, the correction has been uneven. A-share pharmaceutical sub-sectors fell almost across the board, with vaccines, brick-and-mortar pharmacies and other biological products leading the declines. Chen Chen attributed the pullback to the large gains innovative drugs had accumulated earlier; with the interim earnings season over and catalysts from some overseas academic conferences having played out, the sector saw a period of profit-taking—a normal valuation digestion.
Notably, a flurry of recent policy moves failed to effectively support share prices. On November 14, China’s National Healthcare Security Administration and the Ministry of Human Resources and Social Security published the 2026 edition of the national medical insurance drug list and the commercial health insurance innovative drug list. The medical insurance list added 107 drugs, including 51 Class 1 innovative drugs—a record high—while the commercial insurance innovative drug list added 12 drugs for a total of 28.
Chen Chen said the medical insurance negotiations had a success rate of about 86%, while the commercial insurance negotiations had a success rate close to 100%, with multiple innovative drugs successfully entering the reimbursement list—a clear positive signal for the payer side. He cautioned, however, that improved payment coverage does not mean companies are free of pricing pressure; for innovative drugs, it remains to be seen how much prices actually fall after negotiations and whether the “price-for-volume” strategy can truly be delivered. Commercial insurance remains positioned as a supplement to medical insurance, with several bottlenecks in the payment mechanism, and its incremental payment effect on high-priced innovative drugs has yet to fully materialize in the near term. The new list is expected to take effect on January 1, 2027.
Innovative Drug Evaluation Framework Shifts Toward Profitability and Overseas Expansion
The 91 A-share and H-share listed biopharmaceutical companies tracked by UBS Securities posted combined profits of about CNY 5.5 billion (approximately $826.2 million) in the first half of 2026, compared with a combined loss of about CNY 7.4 billion (approximately $1.1 billion) in the same period of 2025—a clear earnings inflection point for the sector as a whole.
Chen Chen noted that the market’s core concern about Chinese biotech companies has been whether R&D spending can ultimately translate into commercialized revenue and profit, and that question is now being gradually answered. On one hand, sales of core products continue to grow and economies of scale are beginning to emerge; on the other, a rise in out-licensing deals is bringing additional revenue and profit contributions. He believes the market’s evaluation framework is shifting from a fixation on R&D pipelines and single clinical data points toward examining whether innovation capabilities can be converted into revenue, profit and cash flow.
Overseas expansion momentum is equally strong. Since the start of 2026, the total value and upfront payments of Chinese companies’ out-licensing deals have both surpassed full-year 2025 levels. Chen Chen observed that demand from large overseas pharmaceutical companies for Chinese innovative assets is extending from relatively single-product licensing to portfolio- and platform-based collaboration models.
CRO Orders Recover; AI Drug Discovery Still Early-Stage
Beyond innovative drugs, CRO and CDMO represent another theme favored by UBS Securities. Chen Chen said new orders and order backlogs at CRO and CDMO companies have grown markedly since the start of 2026, driven on one hand by a recovery in global innovative drug R&D demand and on the other by incremental demand from AI drug discovery.
He explained that under AI-assisted drug discovery (AIDD) and AI for Science models, artificial intelligence can improve the efficiency of early-stage drug discovery and molecular design, but candidate molecules generated by AI must ultimately undergo extensive experimental validation—which in turn further drives demand for CRO and CDMO services.
Upstream data confirms the recovery trend. In the first nine months of 2026, global biopharmaceutical investment and financing totaled about $55.4 billion, up 83% year on year; domestic biopharmaceutical financing in the first 10 months reached about CNY 85.9 billion (approximately $12.9 billion), up 6% year on year. Domestic IND filings have risen 21.8% year on year so far this year, which UBS Securities sees as reflecting a clear recovery in preclinical R&D activity.
On AI drug discovery, UBS Securities’ survey shows that 60% of surveyed biopharmaceutical companies have applied AIDD at various stages of drug R&D and across pipelines, 96% expect to develop AIDD through external resources, and 84% plan to build in-house AIDD capabilities. Chen Chen pragmatically cautioned, however, that AI drug discovery remains at a relatively early stage, with no drug yet discovered by AI that has successfully completed Phase III trials and reached commercial launch. At this stage, the more telling indicators are whether AI can consistently shorten the time from literature review and target discovery to candidate compound generation, and whether it can reduce R&D capital input; over the next two to three years, whether AI drug discovery companies can produce more licensable candidate molecules will be the key metric to watch.
Divergence Ahead: International Capabilities as the Dividing Line
On the outlook, Chen Chen expects the pharmaceutical industry to remain clearly divergent, with the core logic being that different sub-sectors have different sources of revenue and profit and face different payers. If a company’s revenue and profit come mainly from the domestic market, future growth may face pressure, as demographic shifts and medical insurance cost containment remain long-term trends; by contrast, companies with international capabilities and access to overseas revenue have greater room to grow.
UBS Securities is currently focused on three areas: innovative drugs, CRO and AI drug discovery. The core logic for innovative drugs is the combination of improved domestic payment coverage and overseas commercialization; CRO and CDMO benefit from the recovery in global R&D investment and financing and recovering orders; and AI drug discovery represents the long-term trend of improving pharmaceutical R&D efficiency.
After the recent correction, whether pharmaceutical stocks can regain market favor in the near term still depends on capital style and the pace of valuation digestion in previously high-flying sectors. But at the industry level, the earnings inflection point for innovative drugs, continued out-licensing deals, recovering CRO orders and an improving payment system are together forming the fundamental support for the pharmaceutical industry’s next phase. For capital markets, the focus of the pharma trade will gradually shift from simply trading on “innovation expectations” toward verifying whether innovation outcomes can be converted into commercialized revenue, overseas market share and sustained profitability.